Shigella Diarrhoea Prophylaxis Global Market Report 2025

Description

Shigella diarrhoea prophylaxis refers to preventive strategies aimed at reducing the risk of infection caused by Shigella bacteria, which are responsible for acute diarrhoeal illness. This type of prophylaxis targets breaking the transmission cycle of the pathogen by enhancing sanitation, promoting personal hygiene, ensuring safe food and water handling, and implementing public health interventions.

The primary forms of shigella diarrhoea prophylaxis include vaccination, antibiotic prophylaxis, public health initiatives, and hygiene education. Vaccination involves administering a vaccine to activate the immune system against specific pathogens. Vaccines can be given orally, parenterally, or via other routes and are utilized by various end-users including healthcare facilities, travel clinics, pharmacies, and government health programs.

The shigella diarrhoea prophylaxis market research report is one of a series of new reports from The Business Research Company that provides shigella diarrhoea prophylaxis market statistics, including the shigella diarrhoea prophylaxis industry global market size, regional shares, competitors with the shigella diarrhoea prophylaxis market share, detailed shigella diarrhoea prophylaxis market segments, market trends, and opportunities, and any further data you may need to thrive in the shigella diarrhoea prophylaxis industry. This shigella diarrhoea prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The shigella diarrhoea prophylaxis market size has grown strongly in recent years. It will grow from $1.95 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to the rising incidence of shigella infections worldwide, increased awareness regarding food and waterborne illnesses, frequent outbreaks in refugee camps and densely populated urban settings, escalating antibiotic resistance in shigella strains, and a growing number of cases in children under five years old.

The shigella diarrhoea prophylaxis market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The anticipated expansion is driven by the risk of recurrent infections requiring preventive actions, the rise in public health initiatives promoting hygiene, the global prioritization of diarrhoea prevention programs, broader implementation of community health education, and increasing public acceptance and awareness of vaccination. Key trends over the forecast period include progress in vaccine research and development, introduction of innovative oral vaccines targeting shigella, advancements in vaccine delivery methods, creation of broad-spectrum prophylactic treatments, and the availability of rapid diagnostic tools to better direct prophylactic interventions.

The growing awareness of hygiene and sanitation is anticipated to drive the expansion of the shigella diarrhoea prophylaxis market in the coming years. Hygiene and sanitation encompass actions and environmental conditions that promote health and limit disease transmission through cleanliness and proper waste management. This increase in hygiene awareness is fueled by a better understanding of health risks, with more individuals recognizing the critical role cleanliness plays in preventing infectious disease spread. Such awareness supports shigella diarrhoea prophylaxis by reducing person-to-person transmission, as people who practice proper handwashing and waste disposal significantly decrease the chances of spreading the bacteria within communities. For example, in March 2024, the World Health Organization reported that 57% of the global population, or 4.6 billion people, had access to safely managed sanitation services. Of these, 33%, or 2.7 billion people, used private sanitation facilities connected to sewers where wastewater was treated, while 21%, or 1.7 billion people, used toilets or latrines that safely disposed of waste on-site. Thus, the rising awareness of hygiene and sanitation will boost growth in the shigella diarrhoea prophylaxis market.

Leading companies in the shigella diarrhoea prophylaxis market are concentrating on developing advanced solutions like tetravalent bioconjugate shigellosis vaccines to improve immune responses. These tetravalent bioconjugate vaccines are designed to protect against four major Shigella serotypes by linking bacterial polysaccharides to a carrier protein, enhancing the immune response. For instance, in November 2024, Valneva SE, a biotech company based in France, and LimmaTech Biologics AG, a Switzerland-based clinical-stage biotech firm, announced that the first participant had been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2). This vaccine candidate is currently the most clinically advanced tetravalent bioconjugate vaccine targeting shigellosis globally. This represents a key milestone in efforts to develop a vaccine against Shigella, a leading cause of severe diarrheal disease in children. The S4V2 vaccine will be tested for safety and preliminary efficacy in approximately 120 healthy adults aged 18 to 50 who have not previously been exposed to Shigella at three U.S. locations.

In August 2024, Valneva SE, a specialty vaccine company based in France, partnered with LimmaTech to accelerate the development of the advanced tetravalent shigella vaccine candidate. This collaboration allows Valneva to advance a promising program that addresses a critical unmet medical need and highlights LimmaTech's expertise in vaccine development and their capability to rapidly accelerate program progress. LimmaTech is a Switzerland-based company focused on developing the tetravalent shigella vaccine candidate.

Major players in the shigella diarrhoea prophylaxis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Viatris Inc., Chongqing Zhifei Biological Products Co. Ltd., Macleods Pharmaceuticals Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Vaxcyte Inc., Valneva SE, Sanaria Inc., Intravacc B.V., LimmaTech Biologics AG, Eveliqure Biotechnologies GmbH, Intralytix Inc., Immuron Limited, Biocidium Biopharmaceuticals Inc., Institut Pasteur, and Hetero Drugs Limited.

North America was the largest region in the shigella diarrhoea prophylaxis market in 2024. The regions covered in shigella diarrhoea prophylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the shigella diarrhoea prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The shigella diarrhoea prophylaxis market consists of revenues earned by entities by providing services such as water quality testing, educational campaigns, infection control consulting, and food safety services. The market value includes the value of related goods sold by the service provider or included within the service offering. The shigella diarrhoea prophylaxis market also includes sales of hand sanitizers, antibacterial soaps, disinfectants, and surface cleaner. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Shigella Diarrhoea Prophylaxis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on shigella diarrhoea prophylaxis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for shigella diarrhoea prophylaxis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The shigella diarrhoea prophylaxis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Vaccination; Antibiotic Prophylaxis; Public Health Measures; Hygiene Education
2) By Route of Administration: Oral; Parenteral; Other Administrations
3) By End User: Healthcare Facilities; Travel Clinics; Pharmacies; Government Health Programs
Subsegments:
1) By Vaccination: Oral Vaccines; Injectable Vaccines; Combination Vaccines
2) By Antibiotic Prophylaxis: Ciprofloxacin; Azithromycin; Ceftriaxone; Ampicillin; Levofloxacin
3) By Public Health Measures: Water And Sanitation Improvements; Improved Waste Management; Community Health Campaigns
4) By Hygiene Education: Handwashing Campaigns; Safe Food Handling And Preparation Practices; Personal Hygiene Education; Public Awareness Programs
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; GlaxoSmithKline plc; Viatris Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r36064

1. Executive Summary

2. Shigella Diarrhoea Prophylaxis Market Characteristics

3. Shigella Diarrhoea Prophylaxis Market Trends And Strategies

4. Shigella Diarrhoea Prophylaxis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Shigella Diarrhoea Prophylaxis Growth Analysis And Strategic Analysis Framework

5.1. Global Shigella Diarrhoea Prophylaxis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Shigella Diarrhoea Prophylaxis Market Growth Rate Analysis
5.4. Global Shigella Diarrhoea Prophylaxis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Shigella Diarrhoea Prophylaxis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Shigella Diarrhoea Prophylaxis Total Addressable Market (TAM)

6. Shigella Diarrhoea Prophylaxis Market Segmentation

6.1. Global Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vaccination
Antibiotic Prophylaxis
Public Health Measures
Hygiene Education
6.2. Global Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Administrations
6.3. Global Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Healthcare Facilities
Travel Clinics
Pharmacies
Government Health Programs
6.4. Global Shigella Diarrhoea Prophylaxis Market, Sub-Segmentation Of Vaccination,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Vaccines
Injectable Vaccines
Combination Vaccines
6.5. Global Shigella Diarrhoea Prophylaxis Market, Sub-Segmentation Of Antibiotic Prophylaxis,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ciprofloxacin
Azithromycin
Ceftriaxone
Ampicillin
Levofloxacin
6.6. Global Shigella Diarrhoea Prophylaxis Market, Sub-Segmentation Of Public Health Measures,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Water And Sanitation Improvements
Improved Waste Management
Community Health Campaigns
6.7. Global Shigella Diarrhoea Prophylaxis Market, Sub-Segmentation Of Hygiene Education,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Handwashing Campaigns
Safe Food Handling And Preparation Practices
Personal Hygiene Education
Public Awareness Programs

7. Shigella Diarrhoea Prophylaxis Market Regional And Country Analysis

7.1. Global Shigella Diarrhoea Prophylaxis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Shigella Diarrhoea Prophylaxis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Shigella Diarrhoea Prophylaxis Market

8.1. Asia-Pacific Shigella Diarrhoea Prophylaxis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Shigella Diarrhoea Prophylaxis Market

9.1. China Shigella Diarrhoea Prophylaxis Market Overview
9.2. China Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Shigella Diarrhoea Prophylaxis Market

10.1. India Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Shigella Diarrhoea Prophylaxis Market

11.1. Japan Shigella Diarrhoea Prophylaxis Market Overview
11.2. Japan Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Shigella Diarrhoea Prophylaxis Market

12.1. Australia Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Shigella Diarrhoea Prophylaxis Market

13.1. Indonesia Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Shigella Diarrhoea Prophylaxis Market

14.1. South Korea Shigella Diarrhoea Prophylaxis Market Overview
14.2. South Korea Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Shigella Diarrhoea Prophylaxis Market

15.1. Western Europe Shigella Diarrhoea Prophylaxis Market Overview
15.2. Western Europe Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Shigella Diarrhoea Prophylaxis Market

16.1. UK Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Shigella Diarrhoea Prophylaxis Market

17.1. Germany Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Shigella Diarrhoea Prophylaxis Market

18.1. France Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Shigella Diarrhoea Prophylaxis Market

19.1. Italy Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Shigella Diarrhoea Prophylaxis Market

20.1. Spain Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Shigella Diarrhoea Prophylaxis Market

21.1. Eastern Europe Shigella Diarrhoea Prophylaxis Market Overview
21.2. Eastern Europe Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Shigella Diarrhoea Prophylaxis Market

22.1. Russia Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Shigella Diarrhoea Prophylaxis Market

23.1. North America Shigella Diarrhoea Prophylaxis Market Overview
23.2. North America Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Shigella Diarrhoea Prophylaxis Market

24.1. USA Shigella Diarrhoea Prophylaxis Market Overview
24.2. USA Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Shigella Diarrhoea Prophylaxis Market

25.1. Canada Shigella Diarrhoea Prophylaxis Market Overview
25.2. Canada Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Shigella Diarrhoea Prophylaxis Market

26.1. South America Shigella Diarrhoea Prophylaxis Market Overview
26.2. South America Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Shigella Diarrhoea Prophylaxis Market

27.1. Brazil Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Shigella Diarrhoea Prophylaxis Market

28.1. Middle East Shigella Diarrhoea Prophylaxis Market Overview
28.2. Middle East Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Shigella Diarrhoea Prophylaxis Market

29.1. Africa Shigella Diarrhoea Prophylaxis Market Overview
29.2. Africa Shigella Diarrhoea Prophylaxis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Shigella Diarrhoea Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Shigella Diarrhoea Prophylaxis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Shigella Diarrhoea Prophylaxis Market Competitive Landscape And Company Profiles

30.1. Shigella Diarrhoea Prophylaxis Market Competitive Landscape
30.2. Shigella Diarrhoea Prophylaxis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Shigella Diarrhoea Prophylaxis Market Other Major And Innovative Companies

31.1. Chongqing Zhifei Biological Products Co. Ltd.
31.2. Macleods Pharmaceuticals Limited
31.3. Alkem Laboratories Limited
31.4. Alembic Pharmaceuticals Limited
31.5. Vaxcyte Inc.
31.6. Valneva SE
31.7. Sanaria Inc.
31.8. Intravacc B.V.
31.9. LimmaTech Biologics AG
31.10. Eveliqure Biotechnologies GmbH
31.11. Intralytix Inc.
31.12. Immuron Limited
31.13. Biocidium Biopharmaceuticals Inc.
31.14. Institut Pasteur
31.15. Hetero Drugs Limited

32. Global Shigella Diarrhoea Prophylaxis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Shigella Diarrhoea Prophylaxis Market

34. Recent Developments In The Shigella Diarrhoea Prophylaxis Market

35. Shigella Diarrhoea Prophylaxis Market High Potential Countries, Segments and Strategies

35.1 Shigella Diarrhoea Prophylaxis Market In 2029 - Countries Offering Most New Opportunities
35.2 Shigella Diarrhoea Prophylaxis Market In 2029 - Segments Offering Most New Opportunities
35.3 Shigella Diarrhoea Prophylaxis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer